The immunogenicity of the new pneumococcal conjugate vaccine in the elderly

Phase 3

Completed

• Conditions: Pneumococcal disease; Infection - Studies of infection and infectious agents

• Registration Number: ACTRN12607000387426
• Lead Sponsor: Professor C Raina MacIntyre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-07-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 315

Inclusion Criteria

Hospitalized patients

Exclusion Criteria

Younger than 60Previously vaccinated with pneumococcal vaccineAllergic reaction to one of the vaccine componentLife expectancy lees than 12 monthsSeen as unwell to be vaccinated

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immunogenicity (Protein conjugate pneumococcal vaccines are likely to be more <br>immunogenic in adults)[For the PCV7 arm, immunogenicity to PCV7 alone will be measured at 6 months, after which a dose of PPV will be given. At 12 months, the immunogenicity of this PCV7-PPV schedule will be measured. For the PPV arm, immuogenicity to a single dose of PPV will be measured at 6 and 12 months.]

Secondary Outcome Measures

Name	Time	Method
Secondary outcome measures : using a subset of 30% of study participants: pneumococcal serotype specific IgG avidity after each dose to assess immunological memory, functional antibody assays using opsonophagocytosis[To be done at 12 months only]